Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Early Hormone Receptor-positive Breast Cancer 1Breast Neoplasms 1

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Antineoplastic Agents × Breast × Clear all
NCT04004910 2022-03-24

A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients

Immunicom Inc

Phase 1/2 Unknown
170 enrolled
Breast

Breast Neoplasms

NCT04278469 2020-02-20

Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy

Gencurix, Inc.

Phase NA Recruiting
194 enrolled
Breast

Early Hormone Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡